KNect365 is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

RedHill BioPharma takes an antibiotic approach to Crohn's disease

Scrip managing editor Jo Shorthouse talks to RedHill BioPharma, a specialty pharma company in gastrointestinal disease. Its COO, Gilead Raday, explains the company's novel antibiotic approach to Crohn's disease. This candidate, RHB-104, has met its primary and secondary endpoints in a Phase III study, and its candidate RHB-105, for H.pylori infections, is to read out Phase III data in the coming months. He also explains how RedHill BioPharma is spending the $25m it raised in the summer, and what effect this will have on the company's pipeline.

Get the latest news as it happens.